Record

Eli Lilly and Company as of November 8, 2026 · AsOf

organization

Eli Lilly and Company

Eli Lilly and Company is an American pharmaceutical company, headquartered in Indianapolis. It reported revenue of $65.18B for the period ended December 31, 2025.

Headquarters: Indianapolis sec.gov
Revenue: $65.18B to 2025-12-31 sec.gov
Ticker: LLY · NYSE sec.gov

Read the record as of a date

Compare the record on two dates →

State as of 2026-11-08

6 assertedThe record stands behind this value for the day asked: two independent sources agree, or a primary source states it (alone, at confidence 0.7 or more). Everything else stays on the record, labelled.More in About → facts

Eli Lilly and Company: state as of 2026-11-08, one row per fact with its value, date, confidence and sources
fact	value	valid fromThe day the value took effect, not the day it was published. A period figure (a year's revenue) is dated at the period's end.More in About →	confidenceHow well the sources support the value, from 0 to 1. A single primary source is asserted from 0.7; nothing below 0.5 is asserted; a dead or disagreeing source lowers it.More in About →	sourcesPrimary: the entity's own filing, feed or site. Secondary: a publisher reporting it. Each claim links every source it has, with the passage that states the value where one was read.

Latest

0 dated events · full timeline →

No dated events on the record yet.

Releases, deals, appointments and policy changes land here once a checked source dates them.

Every claim on the timeline, including undated ones →

Financials

latest period on record · change vs prior year

Revenue

$65.18B

2025-12-31+44.7%

every revenue figure →

Net income

$20.64B

2025-12-31+94.9%

every net income figure →

Total assets

$148.07B

2026-09-30+28.8%

Cash

$4.88B

2026-09-30-50.1%

As reported in the linked filings, which may be restated. Not investment advice.

State changes since 2026-05-12

18 changes · supersededA later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.More in About →

2026-10-26 · shares outstandingshares outstanding

sec.gov: 1 source for shares outstanding, claim clm_ACF69B8AA825

2026-08-03 · shares outstandingshares outstanding

sec.gov: 1 source for shares outstanding, claim clm_0BBEC8AC9C68 replaced by →

2026-09-30 · total equitytotal equity

About this record

Identifiers7 keys · schema.org snippet

AsOf ID: ent_eli-lilly
Wikidata: Q632240
SEC CIK: 0000059478
fiscal year end: 12-31
SIC industry: Pharmaceutical Preparations (2834)
incorporated in: IN
ticker: LLY

Cite this record in schema.org

"sameAs": ["https://www.wikidata.org/wiki/Q632240", "https://asof.is/record/eli-lilly"],
"identifier": { "@type": "PropertyValue", "propertyID": "asof", "value": "ent_eli-lilly" }

Paste into the entity's JSON-LD. Why and how.

Sources on this entity3 sites · 511 citations

sec.govprimary · 509
med-dept.comsecondary · 1
wikidata.orgsecondary · 1

509 claims on record, 18 currently valid, 491 superseded. Last change 2026-10-26.

quarterly net income	6,451,000,000 United States dollar 2026-09-30sec.gov: 1 source for quarterly net income, claim clm_9D57FD94603E	2026-09-30	0.95	sec.gov: 1 source for quarterly net income, claim clm_9D57FD94603E
quarterly research and development	2,356,500,000 United States dollar 2023-06-30sec.gov: 1 source for quarterly research and development, claim clm_A1B2A03455D9	2023-06-30	0.95	sec.gov: 1 source for quarterly research and development, claim clm_A1B2A03455D9
quarterly revenue	24,397,000,000 United States dollar 2026-09-30sec.gov: 1 source for quarterly revenue, claim clm_E1B01E0405B5	2026-09-30	0.95	sec.gov: 1 source for quarterly revenue, claim clm_E1B01E0405B5
research and development	2022-12-31sec.gov: 1 source for research and development, claim clm_B291C97A9E9C	2022-12-31	0.95	sec.gov: 1 source for research and development, claim clm_B291C97A9E9C
shares outstanding	2026-10-26sec.gov: 1 source for shares outstanding, claim clm_ACF69B8AA825	2026-10-26	0.95	sec.gov: 1 source for shares outstanding, claim clm_ACF69B8AA825
total equity	2026-09-30sec.gov: 1 source for total equity, claim clm_82ACC132512E	2026-09-30	0.95	sec.gov: 1 source for total equity, claim clm_82ACC132512E